Avata Biosciences Emerges to Develop Solid Dose Cannabinoid Medicines for Epilepsy and Other Neurological Diseases
Avata Biosciences Ltd (‘Avata’), the former Sapient Therapeutics, is a clinical-stage biopharmaceutical company with a mission to improve the lives of patients living with neurological diseases.
- Avata Biosciences Ltd (‘Avata’), the former Sapient Therapeutics, is a clinical-stage biopharmaceutical company with a mission to improve the lives of patients living with neurological diseases.
- Meaning ‘to unlock’, Avata is emerging with a new name better aligned to unlock the potential of its proprietary technology to treat large patient populations.
- Avata has assembled a world-class leadership team with a deep scientific understanding of the pharmacological effects, formulation, and drug delivery requirements of cannabinoids.
- SAP-021 will quickly reach blockbuster status, with forecast annual revenues of more than $1B within four years from launch.